Netoglitazone

Netoglitazone is a thiazolidinedione used in the treatment of diabetes mellitus type 2. It functions as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.

Mechanism of action

Netoglitazone works by binding to the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. These receptors are found in fat cells and, when activated, increase the cells' sensitivity to insulin. This results in a decrease in blood glucose levels, helping to manage the symptoms of type 2 diabetes.

Clinical use

Netoglitazone is used in the treatment of type 2 diabetes. It is typically used in combination with other antidiabetic medications, such as metformin or a sulfonylurea. It can also be used alone in patients who cannot tolerate other antidiabetic medications.

Side effects

Like other thiazolidinediones, netoglitazone can cause side effects. These may include weight gain, fluid retention, and an increased risk of heart failure. It can also cause anemia and may increase the risk of bone fractures in women.

History

Netoglitazone was developed by the pharmaceutical company Eli Lilly and Company. It was approved for use in the treatment of type 2 diabetes by the Food and Drug Administration (FDA) in the United States in 1999.

See also

• Thiazolidinedione
• Type 2 diabetes
• Insulin resistance
• Peroxisome proliferator-activated receptors

Netoglitazone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia